Effect of fluconazole on plasma fluvastatin and pravastatin concentrations

European Journal of Clinical Pharmacology

Volumn 56, Issue 3, 2000, Pages 225-229

  Kantola, T ^a   Backman, J T ^a   Niemi, M ^a   Kivisto K T ^a   Neuvonen, P J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Fluconazole; Fluvastatin; Pravastatin

Indexed keywords

CYTOCHROME P450 2C9; FLUCONAZOLE; FLUINDOSTATIN; PRAVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; FATTY ACIDS, MONOUNSATURATED; FEMALE; FLUCONAZOLE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MALE; MIXED FUNCTION OXYGENASES; PRAVASTATIN; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0033920666     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000127     Document Type: Article

References (36)

1. 1. Singhvi SM, Pan HY, Morrison RA, Willard DA (1990) Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 29: 239-243
2. 2. Tse FL, Jaffe JM, Troendle A (1992) Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 32: 630-638
3. 3. Quion JA, Jones PH (1994) Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 27: 94-103
4. 4. Transon C, Leemann T, Dayer P (1993) Selective in vitro P450 inhibition profile by fluvastatin indicates its potential in vivo drug interactions. Clin Pharmacol Ther 53: 188
5. TB (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther 58: 412-417
6. 6. Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT (1999) The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 27: 410-416
7. 7. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH (1991) Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 19: 740-748
8. 8. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U (1999) Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 27: 173-179
9. 9. Back DJ, Tjia JF, Karbwang J, Colbert J (1988) In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 26: 23-29
10. 10. Hargreaves JA, Jezequel A, Houston JB (1994) Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam. Br J Clin Pharmacol 38: 175P
11. 11. Kunze KL, Wienkers LC, Thummel KE, Trager WF (1996) Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 24: 414-421
12. 12. Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, Schentag JJ (1991) Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 49: 420-425
13. 13. Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans JS, Bauwens JE, Trager WF (1996) Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 24: 422-428
14. 14. Varhe A, Olkkola KT, Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56: 601-607
15. 15. Varhe A, Olkkola KT, Neuvonen PJ (1996) Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 41: 319-323
16. 16. Olkkola KT, Ahonen J, Neuvonen PJ (1996) The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82: 511-516
17. 17. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP (1991) Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 151: 43-49
18. 18. Dujovne CA, Chremos AN, Pool JL, Schnaper H, Bradford RH, Shear CL, Higgins J, Downton M, Franklin FA, Nash DT (1991) Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am J Med 91: 25S-30S
19. 19. Anonymous (1997) Rhabdomyolysis seen with simvastatin 160 mg. Reactions 653: 2
20. 20. Kawabata K, Matsushima N, Sasahara K (1998) An automated method for the simultaneous determination of pravastatin and its main metabolite in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Biomed Chromatogr 12: 271-275
21. 21. Harris SC, Wallace JE, Foulds G, Rinaldi MG (1989) Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother 33: 714-716
22. 22. Inagaki K, Takagi J, Lor E, Okamoto MP, Gill MA (1992) Determination of fluconazole in human serum by solid-phase extraction and reversed-phase high-performance liquid chromatography. Ther Drug Monit 14: 306-311
23. 23. Kantola T, Kivistö KT, Neuvonen PJ (1998) Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 63: 397-402
24. 24. Kaminsky LS, Fasco MJ (1992) Small intestinal cytochromes P450. Crit Rev Toxicol 21: 407-422
25. 25. Jurima-Romet M, Crawford K, Cyr T, Inaba T (1994) Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 22: 849-857
26. 26. Kivistö KT, Kantola T, Neuvonen PJ (1998) Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 46: 49-53
27. 27. Christians U, Jacobsen W, Floren LC (1998) Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 80: 1-34
28. 28. Woodland C, Ito S, Koren G (1998) A model for the prediction of digoxin-drug interactions at the renal tubular cell level. Ther Drug Monit 20: 134-138
29. 29. Neuvonen PJ, Jalava KM (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60: 54-61
30. 30. Neuvonen PJ, Kantola T, Kivistö KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63: 332-341
31. 31. Kantola T, Kivistö KT, Neuvonen PJ (1998) Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64: 177-182
32. 32. Kantola T, Kivistö KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64: 58-65
33. 33. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD (1998) The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 64: 369-377
34. 34. Kantola T, Kivistö KT, Neuvonen PJ (1999) Effect of itraconazole on cerivastatin pharmacokinetics. Eur J Clin Pharmacol 54: 851-855
35. 35. Kaukonen KM, Olkkola KT, Neuvonen PJ (1998) Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 53: 445-449
36. 36. Kurosawa M, Okabe M, Kara N, Kawamura K, Suzuki S, Sakurada K, Asaka M (1996) Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells. Ann Hematol 72: 17-21